Le Lézard
Classified in: Health, Science and technology
Subject: TRADE SHOWS/SEMINARS/WEBINARS

Medrio Announces Upcoming Attendance and Exhibit at DIA 2017


SAN FRANCISCO, CA--(Marketwired - June 06, 2017) - Medrio, Inc., a Software as a Service (SaaS) company providing easy-to-use eClinical solutions for clinical trials, will attend the 2017 DIA conference at McCormick Place in Chicago, IL, from June 19 to 21. Company founder and CEO Mike Novotny and Medrio's Sales and Marketing teams will host an outer space-themed exhibit at booth 1054.

The exhibit will offer visitors numerous opportunities for product insight, professional networking, and recreation. Product experts will be offering demonstrations of Medrio's newest electronic data capture (EDC) and eSource products. Mr. Novotny will be holding one-on-one meetings with attendees interested in Medrio's vision and industry thought leadership. There will also be a space-themed game that visitors can play for a chance to win a prize.

Questa Capital Management, who last month finalized a $30 million equity investment in Medrio, will also be present at the conference. That investment will further accelerate the company's already rapid growth, as well as the development and deployment of their new software applications.

"The annual DIA conference is an essential time of year for professionals involved in clinical research, and we always look forward to sharing our industry insight and learning from the thousands of thought leaders in attendance," commented Mike Novotny. "On the heels of the new investment from Questa Capital Management, we're excited to arrive at DIA this year with the wind at our backs. We've got some great things planned for the conference, and look forward to making a splash."

To inquire about Mr. Novotny's availability for a one-on-one meeting, please contact Medrio at [email protected].

About Medrio

Medrio offers an integrated eClinical SaaS platform designed to eliminate paper from clinical trials. Our affordable, cloud-based EDC and eSource products allow data managers to build studies in days instead of months with no IT or programming required, offering unprecedented speed, simplicity, and control in database build and data management. Users also have access to a world-class support staff backed by a top-tier customer satisfaction rating. Medrio has served over 2,000 clinical trials of all phases and therapeutic areas, with an emphasis on early-phase studies. Our software has been used in clinical trials conducted across the globe and submitted to all major regulatory bodies.

For more information, or to schedule an online demonstration or request a free trial, please visit our website.


These press releases may also interest you

at 08:05
Stoke Therapeutics, Inc. , a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Thomas (Tommy) Leggett as Chief...

at 08:05
Cognito Therapeutics, a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today a poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Meeting, held May...

at 08:05
Best Nomos, a TeamBest Global Company, is launching its most modern, highly innovative Compact SONALIS Ultrasound System. Over the past 15 years, Best Nomos has been working on a range of ultrasound systems, and now it's developed and is introducing...

at 08:05
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Eptifibatide for Injection in the United States as a therapeutic equivalent generic for Integrilin® for Injection...

at 08:05
Bonum Therapeutics, a biotechnology company that is using its proprietary platform for conditional regulation to create highly active and less toxic medicines, today announced that it will present data on a new class of protein therapeutics with the...

at 08:05
Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that the U.S. Food and Drug Administration (FDA) accepted the company's Supplemental New Drug...



News published on and distributed by: